ALMS
Alumis Inc. Common StockALMS
ALMS
About: Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
Employees: 147
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
76% more funds holding
Funds holding: 29 [Q2] → 51 (+22) [Q3]
74.09% more ownership
Funds ownership: 0% [Q2] → 74.09% (+74.09%) [Q3]
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]
3% less capital invested
Capital invested by funds: $385M [Q2] → $374M (-$11.4M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
183%
upside
Avg. target
$26
189%
upside
High target
$26
195%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 164 met price target | 195%upside $26 | Buy Reiterated | 20 Dec 2024 |
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 183%upside $25 | Outperform Initiated | 31 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.
Positive
Benzinga
2 months ago
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Positive
Seeking Alpha
2 months ago
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management.
Neutral
GlobeNewsWire
2 months ago
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001's potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasis Full 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE) period of its Phase 2 STRIDE clinical trial of ESK-001.
Positive
Seeking Alpha
3 months ago
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.
Neutral
GlobeNewsWire
3 months ago
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceThursday, September 5, 2024, 8:30 am ETNew York, NY Format: fireside chat and one-on-one investor meetings 2024 Wells Fargo Healthcare ConferenceFriday, September 6, 2024Boston, MA Format: one-on-one investor meetings only Baird 2024 Global Healthcare ConferenceWednesday, September 11, 2024, 8:30 am ETNew York, NY Format: presentation and one-on-one investor meetings; archived webcast replay on Investor Events page of Alumis website for 90 days following the conference 2024 Cantor Fitzgerald Global Healthcare ConferenceTuesday, September 17, 2024, 10:55 am ETNew York, NY Format: fireside chat and one-on-one investor meetings; live webcast on Investor Events page of Alumis website, archived replay available for 90 days following the presentation Stifel 2024 Immunology and Inflammation Virtual SummitWednesday, September 18, 2024, 10:00 am ET Format: presentation About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.
Neutral
GlobeNewsWire
4 months ago
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones.
Neutral
GlobeNewsWire
4 months ago
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program.
Positive
Benzinga
4 months ago
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Positive
Seeking Alpha
5 months ago
U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions
The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment (WBTN) led the week's deals, pricing at the high end to raise $315 million at a $2.8 billion market cap.
Charts implemented using Lightweight Charts™